Andersons pediatric cardiology 2123
Bạn đang xem bản rút gọn của tài liệu. Xem và tải ngay bản đầy đủ của tài liệu tại đây (60.7 KB, 3 trang )
requirementsaftertransplantinpediatricheart
recipients.JHeartLungTransplant.
2011;30(12):1352–1359.
109.LalanS,Abdel-RahmanS,GaedigkA,etal.
EffectofCYP3A5genotype,steroids,andazoles
ontacrolimusinapediatricrenaltransplant
population.PediatrNephrol.2014.
110.deWildtSN,vanSchaikRH,SoldinOP,etal.
Theinteractionsofage,genetics,anddisease
severityontacrolimusdosingrequirementsafter
pediatrickidneyandlivertransplantation.EurJ
ClinPharmacol.2011;67(12):1231–1241.
111.KausmanJY,PatelB,MarksSD.Standard
dosingoftacrolimusleadstooverexposurein
pediatricrenaltransplantationrecipients.Pediatr
Transplant.2008;12(3):329–335.
112.BirdwellKA,DeckerB,BarbarinoJM,etal.
Clinicalpharmacogeneticsimplementation
consortium(CPIC)guidelinesforCYP3A5
genotypeandtacrolimusdosing.ClinPharmacol
Ther.2015;98(1):19–24.
113.DaviesRO,GomezHJ,IrvinJD,WalkerJF.An
overviewoftheclinicalpharmacologyof
enalapril.BrJClinPharmacol.1984;18(suppl
2):215S–229S.
114.LiuL,CuiY,ChungAY,etal.Vectorialtransport
ofenalaprilbyOatp1a1/MRP2andOATP1B1
andOATP1B3/MRP2inratandhumanlivers.J
PharmacolExpTher.2006;318(1):395–402.
115.TianL,LiuH,XieS,etal.Effectoforganic
anion-transportingpolypeptide1b1(OATP1B1)
polymorphismonthesingle-andmultiple-dose
pharmacokineticsofenalaprilinhealthyChinese
adultmen.ClinTher.2011;33(5):655–663.
116.YangD,PearceRE,WangX,etal.Human
carboxylesterasesHCE1andHCE2:ontogenic
expression,inter-individualvariabilityand
differentialhydrolysisofoseltamivir,aspirin,
deltamethrinandpermethrin.Biochem
Pharmacol.2009;77(2):238–247.
117.BobergM,VranaM,MehrotraA,etal.Agedependentabsoluteabundanceofhepatic
carboxylesterases(CES1andCES2)byLCMS/MSproteomics:applicationtoPBPK
modelingofoseltamivirinvivo
pharmacokineticsininfants.DrugMetab
Dispos.2016.
118.JohnsonTN.Theproblemsinscalingadultdrug
dosestochildren.ArchDisChild.
2008;93(3):207–211.
119.KauffmanRE.Clinicaltrialsinchildren:
problemsandpitfalls.PaediatrDrugs.
2000;2(6):411–418.
120.JohnsonTN,Rostami-HodjeganA.Resurgence
intheuseofphysiologicallybased
pharmacokineticmodelsinpediatricclinical
pharmacology:parallelshiftinincorporatingthe
knowledgeofbiologicalelementsandincreased
applicabilitytodrugdevelopmentandclinical
practice.PaediatrAnaesth.2011;21(3):291–301.
121.EdgintonAN,SchmittW,WillmannS.
Developmentandevaluationofageneric
physiologicallybasedpharmacokineticmodel
forchildren.ClinPharmacokinet.
2006;45(10):1013–1034.
122.Abdel-RahmanSM,BreitkreutzML,BiC,etal.
DesignandtestingofanEHR-integrated,
Busulfanpharmacokineticdecisionsupporttool
forthePoint-of-careclinician.FrontPharmacol.
2016;7:65.
123.BestPharmacueticalsforChildrenAct.PubLNo
107-109.
124.PediatricResearchEquityActof2003.PubL
No.108-155.
125.FrattarelliDA,GalinkinJL,GreenTP,etal.Offlabeluseofdrugsinchildren.Pediatrics.
2014;133(3):563–567.
126.SachsAN,AvantD,LeeCS,RodriguezW,
MurphyMD.Pediatricinformationindrug
productlabeling.JAMA.2012;307(18):1914–
1915.
